COL

Leidos selected for Army National Guard aviation training contract

Retrieved on: 
Tuesday, April 9, 2024
Professional, National Guard, LDOS, Information technology, COL, Aviation, Army National Guard, Airline

RESTON, Va., April 9, 2024 /PRNewswire/ -- Leidos (NYSE:LDOS), a Fortune® 500 innovation company, recently was awarded a new prime contract to perform aviation training services and operations support for the Army National Guard.

Key Points: 
  • RESTON, Va., April 9, 2024 /PRNewswire/ -- Leidos (NYSE:LDOS), a Fortune® 500 innovation company, recently was awarded a new prime contract to perform aviation training services and operations support for the Army National Guard.
  • "We're pleased to work with the Army National Guard to support aviation training and operations," said Tim Freeman, Leidos senior vice president and airborne systems business area lead.
  • "The National Guard is one of the nation's oldest institutions, always prepared to protect and defend our country.
  • "Army National Guard Aviation is excited about this new opportunity to join our highly professional Aviation training force with the experience and professionalism that Leidos brings to the fight," said COL A.C. Schilleci, Army National Guard chief aviation and safety division.

Smith+Nephew and U.S. Army Institute of Surgical Research to engage in Master Cooperative Research and Development Agreement

Retrieved on: 
Wednesday, February 28, 2024
Commander, DOD, Life, Master, History, Patient, SNN, CRADA, COL, Development, Sports medicine, Research, Management

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announced they have entered into a Master Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR).

Key Points: 
  • Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announced they have entered into a Master Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR).
  • This marks the first time that the USAISR has entered into a master agreement of this nature with an industry-leading medical technology company.
  • The Master CRADA represents an enterprise-wide opportunity for Smith+Nephew across all business units - Advanced Wound Management, Orthopaedics and Sports Medicine - to enter into multiple collaborative research efforts.
  • “The pre-negotiated key terms and conditions of the Master CRADA provide the broad legal framework under which for multiple, future collaborative research efforts will be assigned.

Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update

Retrieved on: 
Monday, August 14, 2023
COL7, G&A, Cystic fibrosis, Congress, Investigational New Drug, Patient, R, Disease, MYC, Research, Concha bullosa, Alport syndrome, Proteinuria, Cystic Fibrosis Foundation, MAD, COL, Rare, FDA, IND, COL4A4, Collagen, Kidney failure, Skin, Natural history, European Renal Association, Glomerular basement membrane, Cancer, Ultrafiltration, Fibroblast, Colorectal cancer, Radar, Podocyte, Familial adenomatous polyposis, Clinical trial, SAD, FAP, Large intestine, RNA, Trial of the century, Keratinocyte, APC, Food, UPCR, Pharmaceutical industry, Vaccine, Dietary supplement, Health insurance, Alport, RDEB, Creatinine

Podocytes are specialized cells that bind to the glomerular basement membrane and form finger-like extensions called foot processes that enable efficient ultrafiltration.

Key Points: 
  • Podocytes are specialized cells that bind to the glomerular basement membrane and form finger-like extensions called foot processes that enable efficient ultrafiltration.
  • Podocyte injury leads to the effacement (loss) of podocyte foot processes and proteinuria in nearly all cases of Alport syndrome.
  • An IND application for ELX-02 is expected to be submitted to the FDA in the third quarter of 2023.
  • Eloxx remains focused on its liquidity position and is committed to raising additional capital in the near term in order to fund its operating plan through the end of 2023 and beyond.

Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study

Retrieved on: 
Wednesday, May 24, 2023
University College London, Nephrotoxicity, Mutation, RNA, Alport syndrome, Trial of the century, Proteinuria, Nephrology, MD, Patient, NHS foundation trust, RAAS, COL, Rare, Great Ormond Street Hospital, FDA, UPCR, Disease, Pharmaceutical industry, Medical device, Alport

WATERTOWN, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the company intends to advance ELX-02 into a pivotal trial for the treatment of Alport syndrome with nonsense mutations, following the achievement of remission in one patient in its Phase 2 clinical study. The patient demonstrated a significant reduction in urine protein creatinine ratio (UPCR) from baseline. Consistent with prior clinical studies, ELX-02 was well tolerated in this trial.

Key Points: 
  • Consistent with prior clinical studies, ELX-02 was well tolerated in this trial.
  • One patient that has completed dosing achieved a remission, defined as a UPCR decline greater than or equal to 50%.
  • The patient achieving remission also demonstrated a significant reduction (-49%) (-p-value p=0.009) in UPCR from baseline versus values collected over the treatment period.
  • “We are incredibly pleased with these initial findings from our Phase 2 trial of ELX-02 for the treatment of Alport syndrome in patients with nonsense mutations.

University of Phoenix Flag-Planting and Ceremony Honors Fallen Soldiers in Annual Memorial Day Event

Retrieved on: 
Tuesday, May 23, 2023
Education, Defense, Continuing, Other Defense, University, Training, Veterans, Volunteering, Vietnamese American Armed Forces Association, USAF, Military, MBA, Multimedia, University of Phoenix, Gold Star Mothers, John McNulty (U.S. Marine Corps), ARAC, Colour guard, Gold, Doctor, Memorial, Phoenix College, COL, Memorial Day, Management

University of Phoenix held its annual Memorial Day flag-planting event May 23 on its Phoenix campus in Arizona, honoring the sacrifices of those who served and died in the Armed Forces.

Key Points: 
  • University of Phoenix held its annual Memorial Day flag-planting event May 23 on its Phoenix campus in Arizona, honoring the sacrifices of those who served and died in the Armed Forces.
  • This year, volunteers from university employees and community members planted more than 10,000 flags spelling out, “Celebrate, Honor, Remember.”
    This press release features multimedia.
  • On Friday, May 26, the flags will be collected by the nonprofit Arizona Heroes to Hometowns to be distributed at local military cemeteries ahead of Memorial Day.
  • “This event is such an important opportunity to build community and connection with servicemembers and their families,” stated Kathy Pearce of Arizona Heroes to Hometowns .

Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update

Retrieved on: 
Monday, May 15, 2023
COL7, Polyp, Skin, Drug development, Biopsy, Hearing loss, Familial adenomatous polyposis, Survival, Clinical trial, Lead, SAD, G&A, Cystic fibrosis, FAP, Fibroblast, RNA, Alport syndrome, Cancer, Kidney disease, Proteinuria, Genetic disorder, Patient, Keratinocyte, Cystic Fibrosis Foundation, Adenoma, COL, Growth, MAD, APC, Rare, R, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Vaccine, RDEB, Alport

WATERTOWN, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported its financial results for the three months ended March 31, 2023 and provided a business update.

Key Points: 
  • Eloxx has dosed three patients with ELX-02 in the ongoing proof-of-concept Phase 2 open-label clinical trial (NCT05448755).
  • Recent preclinical results demonstrated read-through activity of ZKN-013 in multiple COL7 genotypes across multiple RDEB patient derived fibroblasts and keratinocytes.
  • In January 2023, Eloxx published positive results from a study in the APCMin (multiple intestinal neoplasia) model evaluating the potential of ZKN-013 to treat FAP.
  • In March 2023, we amended the terms of the Hercules Term Loan Agreement and repaid $7.5 million of the outstanding principal.

Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update

Retrieved on: 
Monday, April 3, 2023
COL7, Polyp, Collagen, Skin, Drug development, Hearing loss, Familial adenomatous polyposis, Survival, Clinical trial, Mutation, American Society of Nephrology, G&A, Cystic fibrosis, FAP, Fibroblast, RNA, Alport syndrome, Trial of the century, ASN, Cancer, Proteinuria, COL4A5, Investigational New Drug, Genetic disorder, Patient, COL4A3, Keratinocyte, Kidney, Adenoma, Cystic Fibrosis Foundation, COL, Growth, Epidermolysis bullosa dystrophica, APC, Rare, R, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, COL4A4, Society, Conference, Food, Kidney disease, Pharmaceutical industry, Cryptocurrency, RDEB, Alport

WATERTOWN, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported its financial results for the three months ended December 31, 2022 and provided a business update.

Key Points: 
  • Alport syndrome is a rare genetic disorder characterized by kidney disease with high levels of proteinuria, hearing loss and eye abnormalities.
  • Eloxx presented a poster highlighting the activity of ELX-02 across a range of COL4A5 mutations in preclinical models at the American Society of Nephrology (ASN) Kidney Week 2022 Conference in early November 2022.
  • Recent preclinical results demonstrated read-through activity of ZKN-013 in multiple COL7 genotypes across multiple RDEB patient derived fibroblasts and keratinocytes.
  • R&D expenses were $3.3 million for the three months ended December 31, 2022, which includes $0.3 million in stock-based compensation.

Eloxx Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application for ZKN-013

Retrieved on: 
Tuesday, March 28, 2023
COL7, Polyp, Polyp (medicine), Skin, Drug development, Familial adenomatous polyposis, Survival, Mutation, FAP, Fibroblast, RNA, Cancer, Investigational New Drug, JEB, Patient, Keratinocyte, DSM-IV codes, Adenoma, COL, Growth, Epidermolysis bullosa dystrophica, APC, Rare, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Vaccine, Pharmaceutical industry, RDEB

WATERTOWN, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for ZKN-013 for the treatment of recessive Dystrophic Epidermolysis Bullosa (RDEB) with nonsense mutations. RDEB is a rare skin disease characterized by mutations in Collagen7 gene.

Key Points: 
  • “This IND application is an important milestone towards providing a treatment option for patients with RDEB and JEB, as there are currently no approved disease-modifying treatments,” said Sumit Aggarwal, President and Chief Executive Officer of Eloxx.
  • FAP, a rare inherited disease with no approved drug therapies, is characterized by proliferation of colon polyps.
  • Eloxx is targeting a subset of patients that have nonsense mutations in the Adenomatous Polyposis Coli (APC) gene that is truncated in these patients.
  • In January 2023, Eloxx published positive results from a study in the APCMin (multiple intestinal neoplasia) model evaluating the potential of ZKN-013 to treat FAP.

Creators Retain Full Ownership of Content with Collective's Decentralized Platform

Retrieved on: 
Tuesday, February 7, 2023
Comment, Data collection, Social media, Web 2.0, Mechanics, Android, Peak, Creativity, Internet, Environment, Speech, Growth, COL, IOS, Cryptocurrency

This marks a new era of social media, where users are in the driver's seat, and data security and autonomy are top priorities.

Key Points: 
  • This marks a new era of social media, where users are in the driver's seat, and data security and autonomy are top priorities.
  • Collective , a blockchain-based social media platform, is leading the charge in the decentralized, content-driven space for any participant.
  • The CEO, Bradley James Peak, believes that decentralized systems give authors more control over their creations.
  • Creators and users alike can monetize their social media and self-expression through business and collective likes, rating points, and a referral system.

Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome

Retrieved on: 
Wednesday, January 25, 2023
RNA, Alport syndrome, Safety, Patient, Proteinuria, VII, Mutation, COL4, COL, Cell, Degenerative disease, Pharmaceutical industry, Alport

WATERTOWN, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the first patients have now been enrolled in its Phase 2 study of ELX-02 for the treatment of Alport syndrome in patients with nonsense mutations.

Key Points: 
  • WATERTOWN, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the first patients have now been enrolled in its Phase 2 study of ELX-02 for the treatment of Alport syndrome in patients with nonsense mutations.
  • “With enrollment of the first patients in our Phase 2 study of ELX-02 for the treatment of Alport syndrome in patients with nonsense mutations, we remain on track to deliver topline clinical results from this trial in the first half of 2023,” said Sumit Aggarwal, President and Chief Executive Officer of Eloxx.
  • “ELX-02 treatment has demonstrated restoration of full-length protein in multiple preclinical models, including collagen IV and collagen VII in cells, and also clinical activity in our Phase 2 cystic fibrosis trial.
  • For eligible patients, induction of COL IV will also be measured at the end of two months.